(Q37776162)

23 August 2017

0 references

1 reference

title

Meta-analysis and review on the effect of bevacizumab in diabetic macular edema (English)

1 reference

23 August 2017

0 references

1 reference

2

Michael Lavalley

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20665044

12 June 2024

3

Manju L. Subramanian

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20665044

12 June 2024

author name string

Sunali Goyal

series ordinal

1

1 reference

23 August 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20665044

12 June 2024

publication date

28 July 2010

1 reference

full work available at URL

23 August 2017

http://link.springer.com/content/pdf/10.1007/s00417-010-1452-4.pdf

file format

Portable Document Format

1 reference

https://api.crossref.org/works/10.1007/S00417-010-1452-4

http://link.springer.com/article/10.1007/s00417-010-1452-4/fulltext.html

12 June 2024

1 reference

https://api.crossref.org/works/10.1007/S00417-010-1452-4

http://link.springer.com/content/pdf/10.1007/s00417-010-1452-4

12 June 2024

1 reference

https://api.crossref.org/works/10.1007/S00417-010-1452-4

Graefe's Archive for Clinical and Experimental Ophthalmology

12 June 2024

published in

1 reference

23 August 2017

volume

249

1 reference

23 August 2017

issue

1

1 reference

23 August 2017

page(s)

15-27

1 reference

https://scigraph.springernature.com/pub.10.1007/s00417-010-1452-4

23 August 2017

exact match

0 references

cites work

Diabetic macular edema. A review

1 reference

https://api.crossref.org/works/10.1007%2FS00417-010-1452-4

Risk factors for diffuse and focal macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00417-010-1452-4

The role of growth factors in the pathogenesis of diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00417-010-1452-4

Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00417-010-1452-4

Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with diabetic macular edema and other retinal disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00417-010-1452-4

A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00417-010-1452-4

Anti-angiogenic strategies in gastrointestinal malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00417-010-1452-4

Antivascular endothelial growth factor agents and their development: therapeutic implications in ocular diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00417-010-1452-4

Bevacizumab for neovascular ocular diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00417-010-1452-4

The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00417-010-1452-4

Intravitreal bevacizumab (avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00417-010-1452-4

A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00417-010-1452-4

Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo-controlled, randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00417-010-1452-4

Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00417-010-1452-4

Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00417-010-1452-4

Efficacy of 1.25 MG versus 2.5 MG intravitreal bevacizumab for diabetic macular edema: six-month results of a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00417-010-1452-4

Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00417-010-1452-4

Intravitreal bevacizumab (Avastin) treatment of diffuse diabetic macular edema in an Indian population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00417-010-1452-4

Intravitreal bevacizumab treatment for refractory diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00417-010-1452-4

Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00417-010-1452-4

Efficacy and safety of one intravitreal injection of bevacizumab in diabetic macular oedema.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00417-010-1452-4

Optical coherence tomography and vessel diameter changes after intravitreal bevacizumab in diabetic macular oedema

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00417-010-1452-4

Intravitreal bevacizumab for treatment of diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00417-010-1452-4

The effect of unilateral intravitreal bevacizumab (avastin), in the treatment of diffuse bilateral diabetic macular edema: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00417-010-1452-4

Comparison of two doses of primary intravitreal bevacizumab (Avastin) for diffuse diabetic macular edema: results from the Pan-American Collaborative Retina Study Group (PACORES) at 12-month follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00417-010-1452-4

Intravitreal bevacizumab for diabetic macular edema associated with severe capillary loss: one-year results of a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00417-010-1452-4

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00417-010-1452-4

Meta-analysis: formulating, evaluating, combining, and reporting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00417-010-1452-4

Intravitreal ranibizumab and bevacizumab: a review of risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00417-010-1452-4

Vascular endothelial growth factor biology: clinical implications for ocular treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00417-010-1452-4

Toxicity assessment of intravitreal triamcinolone and bevacizumab in a retinal explant mouse model using two-photon microscopy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00417-010-1452-4

Interventions for diabetic macular oedema: a systematic review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00417-010-1452-4

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00417-010-1452-4

Ten-year incidence of visual loss in a diabetic population

21 January 2018

1 reference

12 December 2020

Intravitreal injection of triamcinolone for diffuse diabetic macular edema

1 reference

12 December 2020

Repeated intravitreal injection of bevacizumab for clinically significant diabetic macular edema

1 reference

12 December 2020

Primary Intravitreal Bevacizumab (Avastin) for Diabetic Macular Edema

1 reference

12 December 2020

Intravitreal bevacizumab versus combined bevacizumab-triamcinolone versus macular laser photocoagulation in diabetic macular edema.

1 reference

12 December 2020

What we don't know about avastin might hurt us

1 reference

12 December 2020

The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema

1 reference

12 December 2020

Intravitreal triamcinolone acetonide for diabetic macula edema

1 reference

12 December 2020

The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years

1 reference

12 December 2020

Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group

1 reference

12 December 2020

Bevacizumab (Avastin) for diabetic macular edema in previously vitrectomized eyes

1 reference

12 December 2020

The role of the vitreous in diabetic macular edema

1 reference

12 December 2020

The Delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus

1 reference

12 December 2020

Twelve-month safety of intravitreal injections of bevacizumab (Avastin®): results of the Pan-American Collaborative Retina Study Group (PACORES)

1 reference

12 December 2020

Pharmacokinetics of intravitreal bevacizumab (Avastin)

1 reference

12 December 2020

A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema

1 reference

12 December 2020

Visual impairment in diabetes

1 reference

12 December 2020

The pathogenesis of edema in diabetic maculopathy

1 reference

12 December 2020

Photocoagulation for Diabetic Macular Edema

series ordinal

8

1 reference

https://api.crossref.org/works/10.1007/S00417-010-1452-4

12 June 2024

Identifiers

1 reference

23 August 2017

1 reference